Xencor Inc. Stock
Price
Target price
€7.75
€7.75
-3.130%
-0.25
-3.130%
€29.59
05.06.25 / Stuttgart Stock Exchange
WKN: A1W96L / Symbol: XNCR / Name: Xencor / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Loading data...
Your prediction
Xencor Inc. Stock
Heavy losses for Xencor Inc. today as the stock fell by -€0.250 (-3.130%).
With 16 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 29 € there is potential for a 274.19% increase which would mean more than doubling the current price of 7.75 € for Xencor Inc..
Pros and Cons of Xencor Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
M***** P*******
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xencor Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xencor Inc. | -3.130% | 15.672% | -9.884% | -61.250% | -66.009% | -60.660% | -70.644% |
| Ironwood Pharmaceuticals | -7.170% | -10.545% | -38.500% | -91.517% | -88.286% | -95.256% | -94.472% |
| Arrowhead Pharmaceuticals Inc. | 3.230% | 4.206% | 28.285% | -35.037% | -20.303% | -54.555% | -51.135% |
| Novocure Ltd | -1.370% | -14.583% | 0.174% | -29.371% | -50.618% | -80.703% | -76.153% |
Comments
Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at Barclays PLC from $22.00 to $6.00. They now have an "underweight" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $31.00 price target on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor, Inc. (NASDAQ: XNCR) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
News
Xencor Reports First Quarter 2025 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the
Xencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel Disease
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced positive interim results
Xencor Appoints Todd Simpson to Board of Directors
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd